Cytotheryx vs Oura

Side-by-side comparison of AI visibility scores, market position, and capabilities

Cytotheryx

EmergingBioTech

Cell Therapy / Liver Disease

Raised $60M Series A (Jan 2026) led by Ouroboros Capital. Mayo Clinic spinout. Engineered pigs as bio-incubators for human hepatocyte production at scale.

About

Cytotheryx is a Mayo Clinic spinout developing human hepatocytes (liver cells) produced at scale using genetically engineered pigs as bio-incubators. The company raised $60 million in Series A financing in January 2026 led by Ouroboros Capital, with GMP (Good Manufacturing Practice) manufacturing expansion underway to support both its acute liver failure support program and transplant-grade cell therapy pipeline.

Full profile

Oura

LeaderConsumer Tech

Smart Health Wearables

Raised $900M Series E at $11B valuation (Oct 2025). CEO projects ~$2B in 2026 sales. Launched women's health LLM (Feb 2026). Team USA LA28 Olympic partner.

About

Oura is the maker of the Oura Ring, a premium smart ring that tracks sleep, recovery, readiness, and health metrics through continuous biometric sensing. The company raised $900 million in Series E financing at an $11 billion valuation in October 2025, reflecting the doubling of its revenue to $500 million in 2024 and a projected $1.5–2 billion in 2026 sales as it expands global distribution into India, UAE, and Latin America.

Full profile

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.